

CUMULATIVE INDEX 1993

Volume 20

March	CURRENT CONTROVERSIES IN PERINATAL CARE II, pages 1-285
June	PERINATAL ASPHYXIA, pages 287-505
September	DIABETES IN PREGNANCY, pages 507-667
December	SURFACTANT REPLACEMENT THERAPY, pages 669-848

Note: Page numbers of issue and article titles are in **boldface** type.

- Abortion, spontaneous, in diabetic pregnancies, 537-538
- Academic career, in neonatal medicine, **1-8**
 - basic science pathway in, 2-3
 - clinical, 6-7
 - fellowship programs for, 3-4
 - motivation for, 2
 - paths for, 2
 - post fellowship programs for, 4
 - research support and, 4-6
 - teaching in, 7
 - training programs for, 2
- Academic function, perinatal asphyxia effects on, 490-491
- Acetoacetate, excessive, in diabetic pregnancies, congenital anomalies and, 523
- Acidemia, in perinatal asphyxia, 290-293, 330-332
- Acidosis, umbilical blood sampling in, 70-71
- Acquired immunodeficiency syndrome. See *Human immunodeficiency virus infection*.
- Addiction, to cocaine. See *Cocaine use*.
- Addiction Severity Index, 35
- Adenosine deaminase deficiency, gene therapy in, 163-164
- Adrenal gland, fetal, in labor initiation, 9-16
- Adrenocorticotrophic hormone, fetal, in labor initiation, 9-14
- Adult respiratory distress syndrome. See *Respiratory distress syndrome (adult)*.
- AIDS. See *Human immunodeficiency virus infection*.
- Airway stabilization, surfactant in, 761-762
- Albumin excretion, in diabetic nephropathy, incipient, 562
- Alcohol abuse, in women, 31-32
 - treatment of, 36-39
- ALEC (artificial lung expanding compound), 818
 - in respiratory distress syndrome (neonatal), 738-739
- Alkalosis, metabolic, induced, in pulmonary hypertension, 136
- Allopurinol, in cerebral hypoxia-ischemia, 413-414
- Alpha adrenergic blocking agents, in hypertension, in diabetic nephropathy, 567
- Alpha tocopherol, in cerebral hypoxia-ischemia, 418
- Alpha-fetoprotein, in congenital anomaly diagnosis, 541-542, 544
- Alveofact. See *SF-R1*.
- Alveolar capillary dysplasia, 131
- Alveolar-arterial oxygen gradient, in pulmonary hypertension, 133
- Amniocentesis, in isoimmune hemolytic disease, 62
- Amniotic fluid, in diabetic pregnancies, prostaglandins in, 639-640
 - volume of, 553
- meconium in, as asphyxia indicator, 328-329
- surfactant extract from, 713, 817
 - in respiratory distress syndrome (neonatal), 725-726
 - in established disease, 719

- Amniotic fluid (*Continued*)
 prophylactic, 716-718
- Androstenedione, fetal, labor initiation and, 15-16
- Anemia, in diabetic nephropathy, 563, 567
 isoimmune hemolytic, erythropoietin therapy in, 179-180
 umbilical blood sampling in, 61-65
 of prematurity, 169-191
 erythropoietin therapy in, 183-186
 normal erythropoiesis and, 170-173
 pathophysiology of, 174-176
- Anencephaly, pregnancy length in, 14-16
- Animal models, of adult respiratory distress syndrome, 769-773
 of gene transfer, 160-165
 of hypoxic-ischemic encephalopathy, 359-363
 of labor, primates as, 14-17
 sheep as, 9-14
 of perinatal asphyxia, magnetic resonance spectroscopy studies of, 359-363
 visual evoked potentials and, 454
 of respiratory distress syndrome (neonatal), surfactant therapy in, 714-715
 of surfactant metabolism, 690-692
- Antiarrhythmic drugs, in fetal tachyarrhythmias, 73
- Antibacterial activity, of surfactant, 763, 765
- Antibiotics, for intrauterine device insertion, 658
- Antibodies, to lung, surfactant depletion from, 771-772
- Antiendotoxin antibody, in streptococcal infections, 219-220
- Anti-inflammatory activity, of surfactant, 765
- Antioxidants, in cerebral hypoxia-ischemia, 417-419
- Aortic valve, atresia of, in hypoplastic left-heart syndrome, 145
- Apgar scores, in perinatal asphyxia, 294-296, 330
- Apnea, recurrent, in surfactant therapy, 750
- Arachidonic acid deficiency, congenital anomalies in, 522, 528
- ARDS. *See Respiratory distress syndrome (adult).*
- Arm ergometry, in gestational diabetes, 627-628
- Artificial lung expanding compound, 818
 in respiratory distress syndrome (neonatal), 738-739
- Asphyxia, perinatal. *See Perinatal asphyxia.*
- Aspiration pneumonia, surfactants in, 775
- Asthma, surfactants in, 779-780
- Atrial flutter/fibrillation, umbilical blood sampling in, 72-73
- Atrioventricular dissociation, congenital, 93-94
- Auditory brain stem evoked potentials, in perinatal asphyxia, 469-470
- Autoimmune disease, maternal, congenital heart block in, 93
- Azathioprine, in heart transplantation, 151-152
- Azidothymidine, in HIV infection, in pregnancy, 48-53
- Bacterial pneumonia, surfactants in, 775-776
- Balance, Wilhelmy-Langmuir, in surfactant surface tension measurement, 669-671
- Base excess, in perinatal asphyxia, 291
- Beractant (Survanta), development of, 713
 in respiratory distress syndrome (neonatal), in animal studies, 818-821
 in established disease, 720-721
 prophylactic, 716-718
- Bergman's minimal model estimation of insulin sensitivity, in gestational diabetes, 587-588
 in pregnancy, 585-586
- Bernard-Soulier syndrome, umbilical blood sampling in, 67
- Beta cell dysfunction, in gestational diabetes, 603-604
- Birth asphyxia. *See Perinatal asphyxia.*
- Blackfan-Diamond syndrome, erythropoietin in, 174
- Bleomycin, pulmonary fibrosis induced by, surfactant therapy in, 779
- Blood flow, cerebral, near infrared spectroscopic quantification of, 371-372
- Blood sampling, umbilical. *See Umbilical blood sampling.*
- Blood volume, cerebral, near infrared spectroscopic quantification of, 372
- Bovine spongiform encephalitis, transmission of, in surfactant therapy, 729-730
- Bradycardia, fetal, delivery route for, 93
- Brain, blood flow in, near infrared spectroscopic quantification of, 371-372
 blood volume of, near infrared spectroscopic quantification of, 372
 computed tomography of, in asphyxia, 380-381
 edema of, after asphyxia, 316
 glucose metabolism in, PET studies of, 396-399

- hemorrhage of, in surfactant therapy, 730
 in thrombocytopenic disorders, 65-67
 SPECT in, 388-389
- hypoxic injury of. See also *Hypoxic-ischemic encephalopathy*.
 irreversible, 312
 near infrared spectroscopy of, 369-378
 infarction in, after asphyxia, 314-315
 SPECT in, 388-389
- normal maturation of, magnetic resonance imaging of, 348-351
 magnetic resonance spectroscopy in, 355
- nuclear magnetic resonance examination of. See *Nuclear magnetic resonance technology*, in perinatal asphyxia.
- ultrasonography of, in asphyxia, 380
- Brain scan, in asphyxia, 382-383
- Breast milk. See *Milk, human*.
- Breastfeeding, 225-243
 infection transmission in, bacterial, 235-236
 cytomegalovirus, 232-233
 Epstein-Barr virus, 234-235
 from mastitis, 236
 from skin lesions, 236
 hepatitis B, 233-234
 herpes simplex virus, 234
 HIV, evidence for, 230-232
 in perinatal period, 229-230
 worldwide perspective of, 228-229
 human T lymphotropic virus type 1, 233
 mechanisms for, 227-228
 proving, 228
 rubella, 234
 toxoplasmosis, 236
 trichinosis, 237
 tuberculosis, 236
 protective effects of, 225-227
- Breathing, fetal, in diabetic pregnancy, 553
- Bronchial smooth muscle, surfactant effects on, 765-766
- Bronchitis, chronic, surfactants in, 781
- Bronchopulmonary dysplasia, in surfactant therapy of RDS, 724, 726, 751-752
- CAGE questionnaire, for substance abuse, 34
- Calcium channel blockers, in cerebral hypoxia-ischemia, 420-421
 in hypertension, in diabetic nephropathy, 567
- Calf lung surfactant extract (Infrasurf), 818
 development of, 713
 in respiratory distress syndrome (neonatal), 725-726, 728
 in animal studies, 818-821
 prophylactic, 716-717
- Captive bubble method, in surfactant surface tension measurement, 672-682
- Cardiomyopathy, hypertrophic, in infant of diabetic mother, 637
- Cardiovascular disorders, fetal/neonatal, in diabetic pregnancies, 519, 637
 maternal, in oral contraceptive use, 652
- Cardiovascular system, cocaine effects on, 249
- Cardiovascular training, in gestational diabetes, 627-628
- Catalase, in cerebral hypoxia-ischemia, 417-418
- Central nervous system. See also *Brain*.
 cocaine effects on, 249
 congenital anomalies of, in diabetic pregnancies, 518-519
- Cerebral blood flow, near infrared spectroscopic quantification of, 371-372
- Cerebral blood volume, near infrared spectroscopic quantification of, 372
- Cerebral palsy, perinatal asphyxia and, 288-289, 488
 PET studies of, 401-407
- Cervix, dilatation of, biologic factors regulating, 21
- Cesarean section, in congenital anomalies. See *Delivery route*, in congenital anomalies.
 indications for, in diabetic pregnancy, 558
- Child abuse, in cocaine use, 256-257
- Chlorpropamide, in gestational diabetes, 606-607
- Cholesterol levels, oral contraceptive effects on, 651-652
- Choreoathetosis, PET studies of, 404, 406
- Chromophores, in brain tissue, near infrared spectroscopy of, 370
- Ciliary activity, in lung, surfactant effects on, 763
- CLSE. See *Calf lung surfactant extract*.
- Cocaine use, in pregnancy, 29-45, 245-262
 administration routes for, 30
 as chronic illness, 29-30
 assessment of, 32-36
 continued in postnatal period, 254-257
 drug combinations with, 257
 epidemiology of, 29
 incidence of, 245-246
 indicators of, 33-34
 mental health issues in, 31, 41, 255-256
 neonatal effects of, birth outcomes and, 250
 caregiving influences and, 254-257
 long-term, 253-254

- Cocaine use (*Continued*)
 neurobehavioral, 250-254
 sensory motor developmental, 252-253
 teratogenic, 248-250
 obstetric complications from, 246-247
 pharmacology of, 246-247
 professional attitudes toward, 32-33
 rehabilitation services for, 38-39
 screening for, 32-36, 247-248
 self-help groups for, 39
 sexual victimization and, 40
 societal stigma for, 32
 sociodemographic factors in, 31-32
 toxicology of, 35-36
 treatment of, 36-41
- Cognitive function, perinatal asphyxia effects on, 490
- Colfosceril palmitate. See CPHT (*synthetic surfactant*).
- Colostrum, immunologic substances in, 227
- Compassionate care, in hypoplastic left-heart syndrome, 152
- Computed tomography, in perinatal asphyxia, 380-381
- Congenital anomalies, antenatal therapy of, 81-83
 cocaine use and, 248-249
 delivery route in. See under *Delivery route*.
 in conjoined twins, 97-99
 in diabetic pregnancies, 517-532, 533-547, 635-636
 clinical manifestations of, 518-520
 diagnosis of, 541-544
 epidemiology of, 517-518
 etiology of, 520
 free oxygen radicals in, 526
 genetic susceptibility and, 527
 incidence of, 533-534
 maternal vasculopathy and, 519-520
 metabolic fuel alterations in, 533-537
 common pathway for, 528
 hyperglycemia, 520-523
 hyperketonemia, 523-524
 hypoglycemia, 525
 prenatal testing for, 541-544
 prevention of, 528-530, 539-541
 somatomedin inhibitors in, 526-527
 spontaneous abortion in, 537-538
 zinc deficiency and, 527
 of heart, erythropoietin therapy in, 179
- Contraception, for diabetic woman, 649-661
 intrauterine device, 656-658
 oral, 650-655
 progestins, 655-656
- Contraction stress test, in diabetic pregnancy, 551-552
- Corticosteroids, in heart transplantation, 151-152
- Corticotropin-releasing hormone, in labor initiation, 10, 12
- Cortisol, fetal, in labor initiation, 9-14
 inhibition of, in lung maturation, 638
 in insulin resistance, 622
- CPHT (Exosurf, synthetic surfactant), composition of, 697-698, 701
 in respiratory distress syndrome (neonatal), 818
 adverse events from, 749-750
 animal studies of, 820-821
 antenatal steroid prophylaxis and, 756
 controlled trials of, 739-741
 dosage of, 754
 in Open Study of Infants at high risk of/with Respiratory Insufficiency, 748-749
 in treatment investigational new drug program, 748
 in very low birth weight infants, 756
 long-term results of, 757
 physiologic issues in, 752-753
 prophylactic, 741-743
 vs. rescue approach, 754, 756
 rescue trials with, 744-748, 754, 756
 safety considerations with, 756-757
 unmet expectation with, 750-752
 vs. mammalian surfactants, 756
 metabolism of, 701-705
 surface tension of, 679-682
- Clq, surfactant protein A homology with, 793
- Crack cocaine. See *Cocaine use*.
- Crying, abnormalities in, from cocaine exposure, 252
- Curosuf, development of, 713
 in respiratory distress syndrome (neonatal), 725, 729
 prophylactic, 718
- Cyclosporine, in heart transplantation, 151-152
- Cystic fibrosis, surfactant therapy in, 777-779
- Cystic hygroma, delivery route for, 89-91
- Cytomegalovirus infection, transmission of, in breastfeeding, 232-233
 umbilical blood sampling in, 68-69
- Deafness, in perinatal asphyxia, 488-489
- Death, in surfactant therapy of RDS, 724-726
 intrauterine, in maternal diabetes, 549-551, 564-565
- Deferoxamine, in cerebral hypoxia-ischemia, 414-415

- Dehydroepiandrosterone, fetal, labor initiation and, 15-16
- Delivery, in diabetic pregnancy, 557-558
lung maturity assessment before, 639-640
- Delivery route, disease transmission and, HIV infection, 229-230
in congenital anomalies, 81-106
conjoined twins, 97-99
cystic hygroma, 89-91
heart block, 92-94
hydrocephalus, 87-89
meningomyelocele, 83-87
monoamniotic twins, 97-99
sacroccygeal teratoma, 91-92
ventral wall defects, 94-97
- Depo-medroxyprogesterone acetate, for diabetic woman, 656
- Detergent aerosol, in surfactant disruption, 770
- Dexamethasone, fetal administration of, labor initiation and, 14, 16
- Diabetes, gestational. See *Gestational diabetes*.
- Diabetes mellitus, classification of, 514
contraception in, 649-661
insulin-dependent, 652-653
intrauterine device, 656-658
non-insulin dependent, 655
oral, 650-655
progestins, 655-656
control of, in nephropathy, 566-567
in pregnancy, 539-540
congenital anomaly rate and, 528-529
in retinopathy, 579
in offsprings of diabetic mothers, 644
in pregnancy, congenital anomalies caused by. See *Congenital anomalies, in diabetic pregnancies*.
control of, 539-540
congenital anomaly rate and, 528-529
fetal growth evaluation in, 542-543
fetal surveillance in, 549-560
contraction stress test in, 551-552
delivery timing and route in, 557-558
Doppler studies in, 554-555
fetal biophysical profile in, 552-553
maternal assessment in, 553-554
nonstress test in, 552
programs for, 555-556
historical review of, 507-515
infant morbidity in. See *Infants of diabetic mothers*.
intrauterine death in, 549-551, 564-565
nephropathy in, 561-570
outcome of, 507-508, 512-515
preconception care in, 539-540
retinopathy in, 571-581
infection in, from intrauterine device, 657-658
nephropathy in. See *Diabetic nephropathy*.
preeclampsia in, 562-563
intrauterine death and, 550
retinopathy in. See *Diabetic retinopathy*.
Diabetic embryopathy. See *Congenital anomalies, in diabetic pregnancies*.
Diabetic nephropathy, in pregnancy, 561-570
clinical features of, 561
incipient, 562-563
long-term effects of, 567-569
overt, 563-564
perinatal outcome in, 564-566
treatment of, 566-567
Diabetic retinopathy, 571-581
classification of, 572-573
in pregnancy, 571-572, 577-580
incidence of, 571-572
nonproliferative, 572
pathophysiology of, 573-577
proliferative, 572-573
treatment of, 572-573, 579-580
Diet, in diabetic nephropathy, 566-567
in gestational diabetes, 605-606, 629-631
Dimethylthiourea, in cerebral hypoxia-ischemia, 418
Dipalmitoyl phosphatidylcholine, in surfactants, natural, 737-738, 815
synthetic, metabolism of, 699-704
synthetic, in respiratory distress syndrome (neonatal), 738
Dipalmitoyl phosphatidylcholine-phosphatidylglycerol mixtures, in respiratory distress syndrome (neonatal), 738-739
Diplegia, spastic, PET studies of, 402-403
Discriminant function analysis, in risk scoring for preterm birth, 109
Dopamine, in pulmonary hypertension, 136
Doppler studies, in fetal surveillance, in diabetic pregnancy, 554-555
Down syndrome, incidence of, in diabetic pregnancies, 542
Drug abuse, cocaine in. See *Cocaine use*.
Drug Abuse Screening Test, 34-35
Ductus arteriosus, patency of, in hypoplastic left-heart syndrome, 147-148
in surfactant therapy, 723, 727, 750
Echocardiography, in pulmonary hypertension, 132
Edema, brain, after asphyxia, 316

Edema (*Continued*)

- pulmonary, surfactant effects on, 762-763
- Embryopathy, diabetic. See *Congenital anomalies, in diabetic pregnancies.*
- Encephalitis, transmission of, in surfactant therapy, 729-730
- Encephalocele, delivery route for, 84
- Encephalopathy, hypoxic-ischemic. See *Hypoxic-ischemic encephalopathy.*
- Endotoxin, antibody to, in streptococcal infections, 219-220
- Enhörning pulsating-bubble surfactometer, in surfactant surface tension measurement, 671-672
- Enteral feeding, of low birth weight infant, advancement of, 197-198
 - hypocaloric, 198
 - initiation of, 197-198
- Epsstein-Barr virus, transmission of, in breastfeeding, 234-235
- Ergometer training, in gestational diabetes, 627-628
- Erythropoiesis, in fetus, 170-172
- Erythropoietin, adverse effects of, 177
 - in anemia of prematurity, 169-191
 - biology of, 172-173
 - levels of, 174-176
 - normal erythropoiesis and, 170-173
 - treatment with, 183-186
- in congenital heart disease, 179
- in end-stage kidney disease, 176-178
- in isoimmune hemolytic anemia, 179
- Estrogens, anti-insulin properties of, 622
 - in oral contraceptives, for diabetic woman, 650-651
- placental, labor initiation and, 13-15, 18-20
- Euglycemic clamp technique, in insulin sensitivity assessment, in gestational diabetes, 588
 - in pregnancy, 585-586
- Evoked potentials, in asphyxia, auditory brain stem, 469-470
 - somatosensory, 458-459, 463-482
 - visual, 451-461, 470-471
- Exercise, in gestational diabetes, 606, 624-629
- Exosurf. See *CPHT (synthetic surfactant).*
- Extracorporeal membrane oxygenation, in pulmonary hypertension, 137-139
 - SPECT in, 388-389

- Fetal monitoring, electronic, as predictor of asphyxia, 293-294
- Fetus, congenital anomalies of, antenatal therapy of, 81-83
 - erythropoiesis in, 170-172
 - growth of, in diabetic pregnancy, 565-566
 - evaluation of, 542-543
 - in gestational diabetes, 611-613
 - in large for gestational age infants, 636-637
 - in small for gestational age infants, 637-638
 - hypothalamic-hypophyseal-adrenal axis of, in labor initiation, 9-14
 - of diabetic mother, breathing movements of, 553
 - growth of, 542-543, 565-566
 - intrauterine death of, 549-551, 564-565
 - malformations in. See *Congenital anomalies.*
 - movement of, 553-554
 - surveillance of, 549-560
 - contraction stress test in, 551-552
 - Doppler studies in, 554-555
 - fetal biophysical profile in, 552-553
 - in gestational diabetes, 556-557
 - lung maturity evaluation in, 558
 - maternal assessment in, 553-554
 - nonstress test in, 552
 - programs for, 555-556
 - tone of, 553
 - small for gestational age, umbilical blood sampling in, 70-71
 - thrombocytopenic disorders in, umbilical blood sampling in, 65-67
 - transition to neonatal circulation in, pulmonary hypertension and, 128-131
 - umbilical blood sampling in. See *Umbilical blood sampling.*
- Fibrosis, pulmonary, surfactants in, 779
- Fluid dispersal, in lung, surfactant effects on, 763
- Flunarizine, in cerebral hypoxia-ischemia, 421
- Folic acid supplementation, in diabetic pregnancies, 540-541
- Fontan procedure, in hypoplastic left-heart syndrome, 149-150
- Free radicals, in diabetic embryopathy, 526, 528
 - inhibitors/scavengers of, in hypoxic-ischemic encephalopathy, 412-419
 - release of, after perinatal asphyxia, 313

Failure to thrive, maternal cocaine use and, 256-257

Fetal biophysical profile, in diabetic pregnancy, 552-553

Gastrointestinal system, congenital anomalies of, in diabetic pregnancies, 519

- Gastroschisis, delivery route for, 94-97
- Gaucher's disease, gene therapy in, 164-165
- Gavage feeding, of low birth weight infants, 203-204
- Gene transfer, into hematopoietic cells, 155-168
 animal models for, 160-165
 indications for, 163-165
 modalities for, 156-160
 Moloney murine leukemia virus in, 156
 packaging cell lines in, 157-159
 safety issues in, 162-163
 target cells for, 159-160
 vector construction in, 156-157
- Genetic factors, in diabetic embryopathy, 527
- Genetically engineered surfactants, 791-811
 in respiratory distress syndrome, animal studies of, 804-808
 surfactant protein characteristics and, 792-804
- Gestational age, perinatal asphyxia and, 309-310
- Gestational diabetes, 603-617, 619-634
 complications of, 611-613
 contraception in, 654-655
 diagnosis of, 584, 593-602
 glucose tolerance test in, 597-600
 screening tests for, 593-597
 fetal surveillance in, 556-557
 glucagon levels in, 587
 glucose levels in, 587
 in obese patients, 605-606
 incidence of, 619
 insulin levels in, 587
 insulin release in, 588-589
 insulin sensitivity in, 587-588
 ketonuria in, 629-630
 lipid levels in, 587
 management of, 605-613
 diet in, 605-606, 629-631
 exercise in, 606, 624-629
 insulin in, 607-610, 613
 optimum glucose levels in, 610-613
 oral hypoglycemic agents in, 606-608, 631
 metabolic changes in, 583-591
 offspring diabetes mellitus development and, 644
 pathogenesis of, 603-605
 pathophysiology of, 620-623
 risk factors for, 594-595, 619-620
 screening for, 594-597
 reasons for, 593-594
 vs. diabetes mellitus, 583
- Glenn anastomosis, in hypoplastic left-heart syndrome, 149-150
- Glibenclamide, in gestational diabetes, 631
- Glomerular filtration rate, in diabetic nephropathy, 563
- Glucagon levels, in gestational diabetes, 587
 in pregnancy, 585
- Glucocerebrosidase deficiency, gene therapy in, 164-165
- Glucose, absorption of, diet effects on, 605
- cerebral, PET studies of, 396-399
 role in hypoxic-ischemic encephalopathy, 421-423
- levels of. See also *Hyperglycemia*; *Hypoglycemia*.
 determination of, strip tests in, 640
 exercise effects on, 624
 in diabetic pregnancies, congenital anomalies and, 520-523, 525-526, 528-529
 in gestational diabetes, 587
 in normal pregnancy, 584-585
 metabolism of, 574-575
 oral contraceptive effects on, 651
- Glucose tolerance test, in gestational diabetes, for diagnosis, 596-600
 for screening, 595-596
- Glutamate toxicity, in cerebral hypoxia-ischemia, 419-420
- Glyburide, in gestational diabetes, 606-607
- Glycohemoglobin, in diabetic pregnancies, congenital anomaly rate and, 535-537
 spontaneous abortion rate and, 537-538
 vs. alpha-fetoprotein levels, 542
- Glypizide, in gestational diabetes, 607
- Graves' disease, maternal, umbilical blood sampling in, 72
- Growth, fetal, in diabetic pregnancy, 565-566
 evaluation of, 542-543
 in gestational diabetes, 611-613
 in large for gestational age infants, 636-637
 in small for gestational age infants, 637-638
 retardation of, susceptibility to perinatal asphyxia in, 310-311
 perinatal asphyxia effects on, 489
- Handicapped infants, very low birth weight, prevalence of, 263-277
- Head circumference, cocaine use and, 250
- Heart, congenital disease of, erythropoietin therapy in, 179
- hypoplastic. See *Hypoplastic left-heart syndrome*.

- Heart (*Continued*)
 transplantation of, in hypoplastic left-heart syndrome, 150-151
- Heart block, congenital, delivery route for, 92-94
- Heart rate, fetal, as asphyxia indicator, 329-330
- HEAT questionnaire, for substance abuse, 34
- Hematopoietic cells, gene transfer into. See under *Gene transfer*.
- Hemiplegia, spastic, PET studies of, 403-404
- Hemoglobin, vs. erythropoietin, 174
- Hemoglobin A1C, in diabetic pregnancies, congenital anomaly rate and, 535-537
 spontaneous abortion rate and, 537-538
 vs. alpha-fetoprotein levels, 542
- Hemolysis, isoimmune, erythropoietin therapy in, 179-180
 umbilical blood sampling in, 61-65
- Hemorrhage, intracranial, in surfactant therapy, 730
 in thrombocytopenic disorders, 65-67
 intraventricular, after asphyxia, 317
 in surfactant therapy of RDS, 723-724
 pulmonary, in surfactant therapy, 730, 749-750
- Hepatitis B, transmission of, 729
 in breastfeeding, 233-234
- Herpes simplex virus, transmission of, in breastfeeding, 234
- Hexadecanol, in synthetic surfactant. See also *CPHT (synthetic surfactant)*.
 metabolism of, 702
- HIV infection. See *Human immunodeficiency virus infection*.
- Hormones, in gestational diabetes, 621-622
- Human immunodeficiency virus infection, cocaine use and, 246-247
 in pregnancy, 49-60
 anti-*Pneumocystis* therapy in, 48, 51, 53-54
 antiviral drugs in, 48-53
 immunotherapy in, 54-56
 pneumonia with, surfactants in, 776
 screening for, in human milk banking, 202
 transmission of, in breastfeeding, evidence for, 230-232
 worldwide perspective of, 228-229
 in delivery, 229-230
 in perinatal period, 229-232
 vertical, 229-230
 azidothymidine effects on, 48-49
 immunotherapy effects on, 54-56
 umbilical blood sampling in, 70
- Human somatomammotropin, metabolic effects of, 623
- Human T lymphotropic virus type 1, transmission of, in breastfeeding, 233
- Hydrocephalus, antenatal treatment of, 89
 delivery route for, 87-89
- Hydrogen peroxide formation, prevention of, in cerebral hypoxia-ischemia, 413-414
- β -Hydroxybutyrate levels, in diabetic pregnancies, congenital anomalies and, 523
- Hyperbilirubinemia, asphyxia-related neurotoxicity and, 362-363
- Hyperglycemia, in diabetic pregnancies, congenital anomalies and, 520-523, 528-529
 intrauterine death and, 550
 protective role of, in hypoxic-ischemic encephalopathy, 422-423
 retinopathy in, 573
- Hyperimmune immunoglobulin therapy, in infections, 218-221
- Hyperinsulinemia, fetal, intrauterine death and, 550-551
 lung maturation and, 638-639
 macrosomia and, 636-637
 neonatal hypoglycemia and, 641
- Hyperketonemia, in diabetic pregnancies, congenital anomalies and, 523-524
- Hypertension, in diabetic nephropathy, 563-564
 control of, 567
 persistent pulmonary. See *Persistent pulmonary hypertension*.
- Hyperthyroidism, umbilical blood sampling in, 71-72
- Hyperventilation, therapeutic, in pulmonary hypertension, 134-135, 139
- Hyperventilation/hyperoxia test, in pulmonary hypertension, 132
- Hypocalcemia, in infant of diabetic mother, 642-643
- Hypoglycemia, in diabetic pregnancies, congenital anomalies and, 525-526
 in infant of diabetic mother, 640-642
- Hypoglycemic agents, oral, in gestational diabetes, 606-608, 631
- Hypomagnesemia, in infant of diabetic mother, 643
- Hypoplastic left-heart syndrome, 145-154
 anatomy of, 145-146
 anomalies associated with, 146
 cardiac transplantation in, 150-152
 compassionate care in, 152
 genetic predisposition to, 146-147
 Norwood operation in, 149-150
 pathophysiology of, 147-148
 preoperative management of, 148-149

- prevalence of, 146
- Hypothalamic-hypophyseal-adrenal axis, fetal, in labor initiation, 9-16
- Hypothermia, in hypoxic-ischemic encephalopathy, 423-425
- Hypothyroidism, umbilical blood sampling in, 71-72
- Hypoxemia, in pulmonary hypertension, 131-133
- repetitive, pathophysiology of, 310
- Hypoxia, fetal, in maternal diabetes, 550
- respiratory distress syndrome treatment response and, 727
- umbilical blood sampling in, 70-71
- Hypoxic-ischemic encephalopathy, 296
- academic function in, 490-491
- animal models of, 359-363
- categories of, 484-488
- cerebral palsy and, 488
- cognitive ability effects of, 490
- computed tomography in, 380-381
- damage mechanisms after, 311-318
- deafness in, 488-489
- factors influencing outcome in, 309-311
- growth effects of, 489
- magnetic resonance imaging in, 351-352
- magnetic resonance spectroscopy in, 355-356
- near infrared spectroscopy in, 369-378
- neuropsychological effects of, 491-495
- PET studies of, 399, 401
- radionuclide brain scan in, 382-383
- sonography in, 380
- SPECT in, 386-392
- therapy for, 411-432
- calcium channel blockers in, 420-421
- excitatory amino acid antagonists in, 419-420
- free radical inhibitors/scavengers in, 412-419
- hypothermia in, 423-425
- primary preventive, 413-416
- secondary interventional, 417-419
- substrate availability considerations in, 421-433
- Immune response, to surfactant therapy, 730
- Immunoglobulin(s), as formula additives, 203
- in human milk, 225-227
- intravenous, in infections, 211-223
- antiendotoxin antibody in, 219-220
- as treatment, 212-215
- hyperimmune type, 218-221
- prophylactic, 215-218
- streptococcal, 218-219
- Immunologic substances, in human milk, 225-227
- Immunosuppressive therapy, in heart transplantation, 151-152
- Immunotherapy, in HIV infection, in pregnancy, 54-56
- in thrombocytopenic disorders, 67
- Infants of diabetic mothers, 635-646
- complications in, 643-644
- congenital anomalies in. *See* *Congenital anomalies*.
- diabetes mellitus development in, 644
- growth disorders in, large for gestational age, 636-637
- small for gestational age, 637-638
- hypocalcemia in, 642-643
- hypoglycemia in, 640-642
- hypomagnesemia in, 643
- intellectual performance in, 643-644
- pulmonary development in, 638-640
- Infarction, brain, after asphyxia, 314-315
- Infections, congenital, umbilical blood sampling in, 67-70
- from intrauterine device, 657-658
- immunoglobulin therapy in, 211-223
- antiendotoxin antibody in, 219-220
- as treatment, 212-215
- hyperimmune type, 218-221
- prophylactic, 215-218
- streptococcal, 218-219
- transmission of, in breastfeeding. *See* *under Breastfeeding*.
- in surfactant therapy, 729-730
- Inflammation, surfactant reduction of, 765
- Influenza, pneumonia in, surfactants in, 775
- Infrasurf. *See* *Calf lung surfactant extract*.
- Insulin, action of, 574
- early clinical trials of, 508-512
- estrogen antagonism of, 622
- in gestational diabetes, 607-610, 613
- levels of, in gestational diabetes, 587
- in pregnancy, 584-585
- pulmonary surfactant synthesis and, 638-639
- release of, in gestational diabetes, 588-589
- in pregnancy, 586
- resistance to, in gestational diabetes, 604-605, 620
- sensitivity to, in gestational diabetes, 587-588
- in pregnancy, 585-586
- teratogenic testing of, 527-528
- Intracranial hemorrhage, in surfactant therapy, 730
- in thrombocytopenic disorders, 65-67
- Intrauterine death, in diabetic nephropathy, 564-565

- Intrauterine death (*Continued*)
 in maternal diabetes, 549-551
 Intrauterine device, for diabetic woman, 656-658
 Intravenous glucose tolerance test, in gestational diabetes, 597, 600
 Intraventricular hemorrhage, after asphyxia, 317
 in surfactant therapy of RDS, 723-724
 Iron elimination, in cerebral hypoxia-ischemia, 414-415
 Isoimmunization, red blood cell, erythropoietin therapy in, 179-180
 umbilical blood sampling in, 61-65
- Kell antibodies, umbilical blood sampling for, 62-63
 Ketoacidosis, in pregnancy, intrauterine death and, 550
 treatment of, 512
 Ketones, in diabetic pregnancies, congenital anomalies and, 523-524
 in gestational diabetes, 629-630
 Kidney, diabetic involvement of. See *Diabetic nephropathy*.
 erythropoietin production in, 172-173
 failure of, erythropoietin therapy in, 176-178
- Labor, biologic basis of, 9-27
 cervical dilatation in, 21
 contracture-to-contraction switch in, 20-21
 fetal hypothalamic-hypophyseal-adrenal axis in, 9-13
 in preterm labor, 21-22
 in primates, 14-17
 in sheep, 9-14
 myometrial activity in, 17-22
 placental events in, 13-14
 prostaglandins in, 13-14, 21
 response to oxytocin and, 20
 stressors in, 22
 cerebral oxygenation assessment during, 375-376
 Large for gestational age infants, maternal diabetes and, 636-637
 La/SSB autoantibodies, congenital heart block and, 93
 Lavage, in surfactant depletion, 771
 Lazeroids, in cerebral hypoxia-ischemia, 418
 Lecithin/sphingomyelin ratio, in diabetic pregnancy, 558, 639-640
 surfactant therapy effects on, 692-693
- Left heart hypoplasia. See *Hypoplastic left-heart syndrome*.
 Levonorgestrel, in oral contraceptives, 651
 Lipid levels, in gestational diabetes, 587
 in pregnancy, 584
 oral contraceptive effects on, 651-652
 Lipid peroxidation, diabetic embryopathy and, 526, 528
 Lipid-extract surfactant, surface tension of, 675, 677
 Liver, erythropoietin production in, 172-173
 Logistic regression, in risk scoring for preterm birth, 110
 Low birth weight infants, handicapped, prevalence of, 263-277
 head circumference of, 250
 nutrition in. See under *Nutrition*.
 Lung. See also *Pulmonary*.
 antibodies to, surfactant depletion from, 771-772
 microstructure of, surfactant surface tension effects on, 669
 transplantation, surfactants in, 776-777
 Lung maturity, fetal, in diabetic pregnancy, 638-640
 evaluation of, 558
 Lymphocytes, in human milk, 227
 Lysophospholipids, antibacterial activity of, 765
- Macrophages, in human milk, 227
 Macrosomia, in diabetes mellitus, 636-637
 in gestational diabetes, pathophysiology of, 611-612
 prevention of, 613
 Magnetic resonance imaging, 346-353
 fundamentals of, 346-348
 in asphyxia, 351-352
 timing of, vs. neurodevelopmental outcome, 352-353
 normal brain maturation and, 348-351
 Malformations, congenital. See *Congenital anomalies*.
 Mannose-binding proteins, surfactant protein A homology with, 793-794
 Mastitis, breastfeeding with, 236
 May-Hegglin anomaly, umbilical blood sampling in, 67
 Mechanical ventilation, in pulmonary hypertension, 134-135
 surfactant therapy with, 730, 750-752
 Meconium aspiration syndrome, surfactants in, 777
 Meconium staining, in asphyxia, 328-329

- Median nerve somatosensory evoked potentials, in perinatal asphyxia, 464-468
- Meningitis, in myelomeningocele, 86
- Meningomyelocele, delivery route for, 83-87
- Mental health issues, in cocaine use, 31, 41, 255-258
- Mestranol, in oral contraceptives, for diabetic woman, 650
- Metabolic alkalosis, induced, in pulmonary hypertension, 136
- Metabolic changes, in gestational diabetes, 583-591
in pregnancy, 584-586
- Metabolic fuel changes, diabetic embryopathy and. *See* *Congenital anomalies, in diabetic pregnancies.*
- Metabolic status, perinatal asphyxia and, 309
- Metformin, in gestational diabetes, 631
- 2-Methylaminochromans, in cerebral hypoxia-ischemia, 418
- N-Methyl-D-aspartate, in cerebral hypoxia-ischemia, 416
- Michigan Alcoholism Screening Test, 34-35
- Microalbuminuria, in diabetic nephropathy, 562
- Microangiopathy, retinal, in diabetes mellitus, 575-577
- Milk, human. *See also* *Breastfeeding.*
bacteria in, 235-236
banking of, 201-202
contamination of, 227-228
for low birth weight infant, 197-198, 200-202
fortifiers for, 200-201
immunologic substances in, 225-227
- Mitral valve, atresia of, in hypoplastic left-heart syndrome, 145
- MK-801, in cerebral hypoxia-ischemia, 420
- Moloney murine leukemia virus, in gene transfer, 156
- Monitoring, fetal, in diabetic pregnancy.
See *Fetus, of diabetic mother, surveillance of.*
- Monoclonal antibodies, in streptococcal infections, 219
- Morbidity index, in perinatal asphyxia, 299-300
- Motor activity, cocaine exposure effects on, 252-253
- Mucous plugs, in surfactant therapy, 750
- Mucus properties, surfactant effects on, 763
in chronic bronchitis, 781
in cystic fibrosis, 777-779
- Multiple organ dysfunction, in perinatal asphyxia, 297-298
- Multivariate risk scoring, for preterm birth, 108-110
- Mycoplasma pneumoniae* pneumonia, pneumonia in, 776
- Myoinositol, deficiency of, in congenital anomalies, 522, 528-529
fetal lung maturation and, 638
- Myometrium, activity patterns of, 17-22
- Nasogastric tube, in enteral feeding, 203
- National Collaborative Perinatal Project, 436-437
- Near infrared spectroscopy, in perinatal asphyxia, 369-378
during labor, 375-376
hemodynamic variable quantification in, 371-372
limitations of, 372-373
principles of, 369-371
- Necrotizing enterocolitis, breast milk protection against, 227
enteral feeding and, 196, 198
- Neonatal medicine, academic career in. *See* *Academic career.*
- Neovascularization, in diabetic retinopathy, 576-577
- Nephrotic syndrome, in diabetic nephropathy, 563
- Neural tube defects, delivery route for, 83-87
prenatal diagnosis of, 83-84
alpha-fetoprotein in, 541-542
prevention of, with folic acid supplementation, 540-541
- Neurobehavioral effects, of cocaine exposure, 250-254
- Neurological disorders, after perinatal asphyxia, 296-297
in pulmonary hypertension, 139
- Neurologic examination, in perinatal asphyxia, 484-489
- Neuropsychologic skills, perinatal asphyxia effects on, 491-495
- Neurotransmitter antagonists, in cerebral hypoxia-ischemia, 419-420
- Nimodipine, in cerebral hypoxia-ischemia, 421
- Nitric oxide, in pulmonary hypertension, 137
- Nitric oxide inhibition, in cerebral hypoxia-ischemia, 415-416
- Nitroglycerin, in pulmonary hypertension, 137
- NCCGDD Nitro-L arginine methyl ester, in cerebral hypoxia-ischemia, 416
- N-Nitroso-N-methyl urea infusion, as ARDS model, 772-773

- Nonnutritive sucking, for preterm infants, 204-205
- Nonstress test, in diabetic pregnancy, 552
- No-reflow phenomenon, in perinatal asphyxia, 312-313
- Norlethindrone, in oral contraceptives, for diabetic woman, 651
- Norplant, for diabetic woman, 656
- Norwood operation, in hypoplastic left-heart syndrome, 149-150
- Nuclear magnetic resonance spectroscopy, 353-363
 fundamentals of, 353-354
 in asphyxia, 355-356, 359-363
 modifications of, 356-357
 normal brain maturation and, 355
 proton, 357-359, 361-362
- Nuclear magnetic resonance technology, in perinatal asphyxia, 345-367
 imaging, 346-353
 spectroscopy, 353-363
- Nutrition. *See also Breastfeeding.*
 in low birth weight infant, 193-209
 advancement of, 197-198
 feeding methods for, 203-204
 formulas for, 202-203
 goals of, 193-197
 human milk in, 197-198, 200-202
 initiation of, 197-198
 long-term effects of, 196-197
 milk banking in, 201-202
 nonnutritive sucking with, 204-205
 theoretical requirements in, 194
- Obesity, gestational diabetes in, 605-606
- Omphalocele, delivery route for, 94-97
- Open Study of Infants at high risk of, or with, Respiratory Insufficiency, surfactants in, 748-749
- Oral glucose tolerance test, in gestational diabetes, for diagnosis, 596-600
 for screening, 595-596
- Oral hypoglycemic agents, in gestational diabetes, 606-608, 631
- Orogastric tube, in enteral feeding, 203
- Osteopetrosis, gene therapy in, 164
- Oxygen, partial pressure of, in pulmonary hypertension, 132-133
- Oxygen therapy, in small for gestational age fetus, 71
- Oxygen toxicity model, of ARDS, 772
- Oxygenation, evaluation of, in pulmonary hypertension, 132-133
- Oxygenation index, in pulmonary hypertension, 133
- Oxygen-free radical inhibitors/scavengers, in hypoxic-ischemic encephalopathy, 412-419
- Oxypurinol, in cerebral hypoxia-ischemia, 414
- Oxytocin, antagonists to, in preterm labor, 21-22
 secretion of, diurnal rhythm of, 20
- Parenteral nutrition, for low birth weight infant, 197-198
- Parenting, cocaine use effects on, 254-257
- Parvovirus infection, umbilical blood sampling in, 69
- Patent ductus arteriosus, in surfactant therapy, 750
 in surfactant therapy of RDS, 723
 respiratory distress syndrome treatment response and, 727
- Pedersen's theory, of macrosomia, 611-612, 636-637
- Pelvic inflammatory disease, from intrauterine device, 657-658
- Pentamidine, in *Pneumocystis* prophylaxis, in pregnancy, 53-54
- Peptides, synthetic, in surfactant compositions, 824-826
- Percutaneous umbilical blood sampling. *See Umbilical blood sampling.*
- Perinatal asphyxia, acidemia in, 290-293, 330-332
 adaptive responses to, 306-307
 animal models for, 359-363, 454
 Apgar scores in, 294-296, 330
 as syndrome, 332-335
 auditory brain stem evoked potentials in, 469-470
 base excess in, 291
 biochemical indices of, 289
 biologic risks for, 433-449
 confounding issues in, 434-436
 brain edema after, 316
 brain infarction after, 314-315
 brain scanning in, 382-383
 cerebral palsy and, 288-289, 488
 computed tomography in, 380-381
 definition of, 287-304
 depression phase after, 313-314
 differential diagnosis of, 338-339
 encephalopathy in. *See Hypoxic-ischemic encephalopathy.*
 environmental issues in, 436
 experimental, 337-338
 fetal heart rate and, 329-330
 fetal monitoring prediction of, 293-294
 free radical release in, 313
 gestational age and, 309-310

- historical perspectives on, 288-289
hyperbilirubinemia and, 362-363
in growth retardation, 310-311
in umbilical cord occlusion, 310
indicators of, 327-344
 as single elements, 328-332
 elements together, 332-335
 later, 332
long-term effects of, 483-500
 academic function, 490-491
 cognitive ability, 490
 growth, 489
 neonatal neurologic examination in, 484-489
 neuropsychologic skills, 491-495
 sexual maturation, 490
meconium staining in, 328-329
metabolic status in, 309
morbidity index in, 299-300
multiple organ dysfunction in, 297-298
near infrared spectroscopy in, 369-378
neurologic examination in, 484-489
neurological sequelae of, 296-297
no-reflow phenomenon in, 312-313
nuclear magnetic resonance technology in, 345-367
 imaging, 346-353
 spectroscopy, 353-363
pathophysiology of, 305-325
 adaptive responses in, 306-307
 factors influencing, 309-311
 primary causes in, 335-336
 secondary damage, 311-318, 335-336
 severe, 307-308
placental pathology in, 336
positron emission tomography in, 399, 401
recovery profiles in, 314
reperfusion after, 312-313
repetitive hypoxemia and, 310
respiratory distress syndrome treatment response and, 727
secondary damage in, 311-318
seizures after, 315-316
severe, pathophysiology of, 307-308
single photon emission computed tomography in, 379-394
somatosensory potentials in, 458-459, 463-482
sonography in, 380
stroke after, 316-317
visual evoked potentials in, 451-461, 470-472
Peroxidation, lipid, diabetic embryopathy and, 526, 528
Persistent pulmonary hypertension, 127-143
 alveolar capillary dysplasia in, 131
 diagnosis of, 131-133
 epidemiology of, 127-128
 excessive vascular muscularization in, 131
 maladaptive form of, 129-131
 neurodevelopmental outcome in, 138-139
 pathophysiology of, 128-131
 treatment of, 133-138
 vascular malalignment in, 131
PET. See *Positron emission tomography*.
Phase-modulated rotating frame imaging, as nuclear magnetic resonance spectroscopy modification, 357
Phosphatidylcholine, in surfactants, 815
 metabolism of, 698-699
 synthesis of, 698
Phosphatidylglycerol, in surfactants, natural, 700, 815
 synthetic, 738
Phosphatidylinositol, in natural surfactants, 815
Phospholipid(s), in surfactants, 815-816
Pituitary gland, fetal, in labor initiation, 9-16
Placenta, abnormalities of, in perinatal asphyxia, 336
 progesterone in, labor initiation and, 13-14
Platelet transfusion, in thrombocytopenic disorders, 66-67
Pneumocystis carinii, chemotherapy for, in pregnancy, 48, 51, 53-54
Pneumonia, surfactant therapy in, 774-776
Pneumothorax, in surfactant therapy of RDS, 722-723, 726
Polio virus antibodies, in human milk, 226
Polyethylene glycol-catalase, in cerebral hypoxia-ischemia, 417-418
Polyethylene glycol-superoxide dismutase, in cerebral hypoxia-ischemia, 417-418
Polyol pathway, in diabetes mellitus, 575
Positron emission tomography, 395-409
 dosimetry in, 396
 in cerebral palsy, 401-407
 in perinatal asphyxia, 399, 401
 normative data in, 396-399
 principles of, 395-396
Prednisone, in heart transplantation, 151-152
Preeclampsia, in diabetic nephropathy, 562-564
 intrauterine death and, 550
Pregnancy, anti-*Pneumocystis* therapy in, 48, 51, 53-54
 cocaine addiction in. See under *Cocaine use*.
 diabetes in. See *Diabetes mellitus; Gestational diabetes*.
 exercise in, safety of, 624-626

- Pregnancy (*Continued*)
 glucagon levels in, 585
 glucose levels in, 584-585
 HIV infection in, treatment of, 49-60
 immunotherapy in, in HIV infection, 54-56
 insulin sensitivity in, 585-586
 lipid levels in, 584
 umbilical blood sampling in. See *Umbilical blood sampling*.
- Premature infants, low birth weight. See *Low birth weight infants*.
- respiratory distress syndrome in. See *Respiratory distress syndrome (neonatal)*.
- surfactant metabolism in, 687-690
 surfactant pool size in, 684-686
- Prematurity, anemia of. See *Anemia, of prematurity*.
- Preterm birth, of infants of diabetic mothers, with nephropathy, 566
- risk scoring for, 107-125
 definitions in, 119-120
 difficulties with, 118-122
 evaluation of, 110-111
 literature review of, 115-118
 methods for, 107-110
 population specificity of, 120-121
 predictive value of, 111
 preventive interventions and, 120
 reliability of, 111
 review of, 111-115
 risk factor identification in, 118-119
 sensitivity of, 110-111
 specificity of, 110-111
 statistical limitations of, 121-122
- Preterm labor, biochemical factors in, 21-22
- Progestasert, for diabetic woman, 657
- Progesterone, glucose metabolism effects of, 622
 placental, labor initiation and, 13-14
- Progestins, glucose metabolic effects of, 651
 in contraceptives, for diabetic woman, long-acting, 655-656
 oral, 650
 lipid levels affected by, 651-652
- Prolactin, metabolic effects of, 622-623
- Propylthiouracil, fetal hypothyroidism from, 72
- Prostaglandins, in amniotic fluid, in diabetic pregnancies, 639-640
 in labor initiation, 13-14, 20-21
 in pulmonary hypertension, 137
- Protein(s), dietary restriction of, in diabetic nephropathy, 566-567
 surfactant. See *Surfactant protein(s)*.
- Proteinuria, in diabetic nephropathy, incipient, 562-563
 overt, 563-564
- Proton magnetic resonance spectroscopy, 357-359, 361-362
- Pulmonary disorders, surfactant in. See *Surfactant(s), in pulmonary disorders*.
- Pulmonary edema, surfactant effects on, 762-763
- Pulmonary fibrosis, surfactants in, 779
- Pulmonary hemorrhage, in surfactant therapy, 730, 749-750
- Pulmonary hypertension, persistent. See *Persistent pulmonary hypertension*.
- Pulmonary maturity, fetal, in diabetic pregnancy, evaluation of, 558
- Pulmonary pressure, measurement of, in pulmonary hypertension, 132
- Pulmonary surfactant. See *Surfactant(s)*.
- Pulsating-bubble surfactometer, in surfactant surface tension measurement, 671-672
- Quadriplegia, spastic, PET studies of, 402
- Radiation pneumonitis, surfactants in, 779
- Radionuclide brain scan, in asphyxia, 382-383
- Rat, surfactant from, surface tension of, 675
- RDS. See *Respiratory distress syndrome*.
- Recombinant surfactant proteins, 823-824
- Red blood cell(s), gene transfer into, for disease treatment, 163-164
- Red blood cell isoimmunization, erythropoietin therapy in, 179-180
 umbilical blood sampling in, 61-65
- Rehabilitation services, for cocaine addiction, 38-39
- Reperfusion, after perinatal asphyxia, 312-313
- Research, as academic career, 2-7
- Respiratory distress syndrome (adult), 766-774
 pathogenesis of, 766-769
 surfactant abnormalities in, mechanisms of, 767-769
 replacement of, in animal models, 769-773
 surfactant therapy in, 773-774
 third-generation, 826
- Respiratory distress syndrome (neonatal), in infant of diabetic mother, 639
 prevention of, 715-718, 725-726
 surfactants in. See *Surfactant(s), in respiratory distress syndrome (neonatal)*.
- Retinopathy, diabetic. See *Diabetic retinopathy*.

- Retroviruses, in gene transfer. See *Gene transfer*.
- Risk scoring, for preterm birth. See under *Preterm birth*.
- Ro/SSA autoantibodies, congenital heart block and, 93
- Rotavirus antibodies, in human milk, 226-227
- RU486, in labor initiation, 16-17
- Rubella, transmission of, in breastfeeding, 234
- Sacrococcygeal teratoma, delivery route for, 91-92
- Screening, for cocaine use, in pregnancy, 32-36, 247-248
for preterm birth. See *Preterm birth, risk scoring for*.
- Seizures, postasphyxial, 315-316
- Self-help groups, for substance abuse, 39
- Sendai virus, pneumonia in, surfactants in, 775
- Sensory motor activity, cocaine exposure effects on, 252-253
- Sepsis, neonatal, immunoglobulins in, as prophylaxis, 215-218
as therapy, 212-215
- Sexual maturation, perinatal asphyxia effects on, 490
- Sexually transmitted diseases, in diabetic woman, 658
- SF-R1 (Alveofact surfactant), development of, 713
in respiratory distress syndrome (neonatal), in established disease, 720
prophylactic, 718
- Siamese twins, delivery route for, 97-99
- Single photon emission computed tomography, clinical applications of, 383-384
in asphyxia, 386-392
in cerebral infarction/hemorrhage, 388-389
in extracorporeal membrane oxygenation, 388-389
in neonates, 385
in pediatric patients, 384-385
normal appearance in, 386
normative values for blood flow in, 385-386
- Small for gestational age fetus, umbilical blood sampling in, 70-71
- Small for gestational age infants, maternal diabetes and, 637-638
- Smoke inhalation, in surfactant deactivation, 770-771
- Smooth muscle relaxation, surfactant in, 765-766
- Somatomedin inhibitors, diabetic embryopathy and, 526-527
- Somatosensory evoked potentials, in perinatal asphyxia, 463-482
median nerve, 464-468
posterior tibial nerve, 468-469
vs. visual evoked potentials, 458-459, 470-472
- Sonography, in perinatal asphyxia, 380
- Sorbitol, in hyperglycemia, 522, 528, 575
- Spastic diplegia, PET studies of, 402-403
- Spastic hemiplegia, PET studies of, 403-404
- Spastic quadriplegia, PET studies of, 402
- SPECT. See *Single photon emission computed tomography*.
- Spectroscopy, in perinatal asphyxia, near infrared, 369-378
nuclear magnetic resonance, 353-363
- Stem cells, hematopoietic, gene transfer into. See under *Gene transfer*.
- Stillbirth. See *Intrauterine death*.
- Streptococcal infections, immunoglobulin therapy in, 218-219
- Stress, maternal, preterm labor in, 22
- Strip tests, for glucose, 640
- Stroke, after asphyxia, 316-317
- Substance abuse, cocaine in. See *Cocaine use*.
- Sucking, nonnutritive, for preterm infants, 204-205
- Sudden infant death syndrome, cocaine use and, 250
- Superoxide dismutase, diabetic embryopathy and, 526
in cerebral hypoxia-ischemia, 417-418
- Superoxide radical formation, prevention of, in cerebral hypoxia-ischemia, 413-414
- Supraventricular tachycardia, umbilical blood sampling in, 72-73
- Surface tension, of surfactant. See under *Surfactant(s)*.
- Surfactant(s), antibacterial activity of, 763, 765
anti-inflammatory activity of, 765
biosynthesis of, 698-699
insulin effects on, 638
bovine, 818
development of, 712-713
in respiratory distress syndrome (neonatal), 725-726, 729
in established disease, 720
prophylactic, 716
ciliary motility and, 763
clearance of, 699-700
deficiency of, in ARDS, 767
designer, 813-829

Surfactant(s) (*Continued*)

- natural surfactants and, biophysical properties of, 814-815
- composition of, 815-816
 - mammalian-based, 817-818
- recombinant, 823-824
- synthetic peptides, 824-826
- synthetic surfactants and, 818
- third-generation, 821-826
- vs. currently available surfactant preparations, 818-821
- extra-alveolar, mechanism of action, 761-762
- from amniotic fluid, 713, 817
 - in respiratory distress syndrome (neonatal), 725-726
 - in established disease, 719-720
 - prophylactic, 716-718
- function of, vs. metabolism, 694
- genetically engineered, 791-811
 - in respiratory distress syndrome, animal studies of, 804-808
 - surfactant protein characteristics and, 792-804
- heterologous, definition of, 712
- homologous, definition of, 712
- in adult respiratory distress syndrome, 766-774, 826
- in airway stabilization, 761-762
- in asthma, 779-780
- in chronic bronchitis, 781
- in cystic fibrosis, 777-779
- in edema reduction, 762-763
- in fluid dispersal, 763
- in lung transplantation, 776-777
- in meconium aspiration, 777
- in mucus property alteration, 763
- in pneumonia, 774-776
- in pulmonary disorders, 761-789. *See also subhead: in respiratory distress syndrome.*
- adult respiratory distress syndrome, 766-774
 - asthma, 779-780
 - chronic bronchitis, 781
 - cystic fibrosis, 777-779
 - lung transplantation, 776-777
 - mechanism of action, 761-766
 - meconium aspiration, 777
 - pneumonia, 774-776
 - pulmonary fibrosis, 779
- in pulmonary fibrosis, 779
- in respiratory distress syndrome (adult), 766-774
 - third-generation surfactants in, 826
- in respiratory distress syndrome (neonatal), 711-735
 - bronchopulmonary dysplasia in, 724
 - complications of, 729-731
 - dosage effects on, 728-729
 - factors affecting response, 727-729
 - genetically engineered, 804-808
 - in animal models, 714-715
 - in established disease, 719-721, 725-726
 - intraventricular hemorrhage in, 723-724
 - lack of response to, 727
 - long-term results of, 731
 - metabolism of, 690-693
 - mortality in, 724-725
 - patent ductus arteriosus in, 723
 - pneumothorax incidence in, 722-723
 - prophylactic, 715-718, 725-726
 - protein metabolism in, 693-694
 - surfactant quality effects on, 727-728
 - in smooth muscle relaxation, 765-766
 - inactivation of, in ARDS, 767-768
 - lamellar form of, 698
 - lipid-extract, surface tension of, 675, 677
 - lung-associated (not recoverable by washing), 689
 - mechanism of action of, 761-766
 - metabolism of, 683-696, 699-700
 - in adult, 687
 - in animal models, 690-692
 - in preterm lung, 687-690
 - in respiratory distress syndrome (neonatal), 692-693
 - in treatment, 690-694
 - overview of, 686-687
 - surfactant function and, 694
 - surfactant pool size and, 684-686
 - surfactant proteins and, 693-694
 - synthetic, 697-710
- natural, 711-735
 - absorption of, 815
 - biophysical properties of, 814-815
 - chemical composition of, 712
 - composition of, 737-738, 815-816
 - development of, 712-714
 - in respiratory distress syndrome (neonatal), bronchopulmonary dysplasia in, 724
 - complications of, 729-731
 - factors affecting response, 727-729
 - in animal models, 714-715
 - in established disease, 719-721, 725-726
 - intraventricular hemorrhage in, 723-724
 - long-term results of, 731
 - mortality in, 724-725
 - patent ductus arteriosus in, 723
 - pneumothorax incidence in, 722-723
 - prophylactic, 715-718, 725-726
 - phospholipids of, 815-816
 - pool size of, measurement of, 684

- surfactant metabolism and, 684-686
- porcine, 818
- development of, 713
- in respiratory distress syndrome (adult), 774
- in respiratory distress syndrome (neonatal), 725-726, 728
- in established disease, 720
- prophylactic, 718
- quality of, treatment response and, 727-728
- rat, surface tension of, 675
- secretion of, 698-699
- surface tension properties of, 669-682
- effects on lung microstructure, 669
- measurement of, 669-682
- captive bubble method, 672-682
- Enhörning pulsating-bubble surfactometer in, 671-672
- Wilhelmy-Langmuir balance in, 669-671
- synthetic, 818. See also specific product, e.g., CPHT.
- in respiratory distress syndrome (adult), 774
- in respiratory distress syndrome (neonatal), 737-760
- artificial lung expanding compound, 738-739
- CPHT, 739-757
- early trials of, 738
- in established disease, 744-748
- metabolism of, 701-705
- overview of, 700-701
- Surfactant protein(s), functions of, 700-701, 713-714
- in natural surfactant extracts, 713-714
- metabolism of, 693-694
- surface tension effects of, 675, 677
- synthesis of, 698
- types of, 792
- Surfactant protein A, antibacterial activity of, 765
- cellular origin of, 795-796
- characteristics of, 792-796
- chemical structure of, 792-793
- composition of, 816
- immunogenicity of, 730
- metabolism of, 689
- recombinant, 823-824
- surface tension effects of, 677
- Surfactant protein B, characteristics of, 796-801
- chemical structure of, 796-798
- composition of, 816
- gene of, 799-800
- mechanism of action of, 800-801
- metabolism of, 690
- peptides related to, in surfactant compositions, 824-826
- recombinant, 823
- secretion of, 798-799
- Surfactant protein C, characteristics of, 796, 801-804
- composition of, 816
- gene of, 802-803
- genetically engineered, 804-807
- in respiratory distress syndrome (neonatal), 804-807
- structure of, 801-802
- Surfactant protein D, 792, 794, 808
- Surfactant-TA, development of, 712-713
- in respiratory distress syndrome (neonatal), clinical trials of, 715
- factors affecting response, 727-728
- in established disease, 719
- prophylactic, 718
- Surfacten. See *Surfactant-TA*.
- Surfactometer, Enhörning pulsating-bubble, in surfactant surface tension measurement, 671-672
- Survanta. See *Beractant*.
- Synthetic surfactants. See under *Surfactant(s)*.
- Syphilis, umbilical blood sampling in, 70
- Tachyarrhythmia, umbilical blood sampling in, 72-73
- Taurine supplementation, in formulas, 202-203
- Teratogenic effects, of cocaine, 248-250
- of hyperglycemia, 520-523, 528-529
- of hyperketonemia, 523-524
- of oral hypoglycemic agents, 631
- of vitamin A, 527
- of zinc deficiency, 527
- Teratoma, sacrococcygeal, delivery route for, 91-92
- Thyroid disease, umbilical blood sampling in, 71-72
- Tibial nerve (posterior) somatosensory evoked potentials, in perinatal asphyxia, 468-469
- Tirilazad mesylate, in cerebral hypoxia-ischemia, 418
- Tolazoline, in pulmonary hypertension, 137
- Tolbutamide, in gestational diabetes, 606-607
- Toxoplasmosis, transmission of, in breastfeeding, 236
- umbilical blood sampling in, 67-68
- Training, for academic career. See *Academic career*.
- Transfusion, fetal hemoglobin loss during, 175-176

- Transfusion (*Continued*)
 intrauterine, in isoimmune hemolytic disease, 63-65
 platelet, in thrombocytopenic disorders, 66-67
 Transplantation, heart, in hypoplastic left-heart syndrome, 150-151
 lung, surfactants in, 776-777
 Transpyloric feeding, of low birth weight infants, 204
 Trichinosis, transmission of, in breastfeeding, 237
 Trimethoprim-sulfamethoxazole, in *Pneumocystis* prophylaxis, in pregnancy, 53-54
 Tuberculosis, transmission of, in breastfeeding, 236
 Twins, delivery route for, conjoined, 97-99
 monoamniotic, 97-99
 Tyloxapol. See also CPHT (*Exosurf, synthetic surfactant*).
 in synthetic surfactant, metabolism of, 704-705
- U-74006F (tirilazad mesylate), in cerebral hypoxia-ischemia, 418
 U-78517F (2-methylaminochromans), in cerebral hypoxia-ischemia, 418
 Ultrasonography, in diabetic pregnancies, 542-544, 554-555
 in perinatal asphyxia, 380
 Umbilical blood sampling, 61-80
 in Bernard-Soulier syndrome, 67
 in congenital infections, 67-70
 in cytomegalovirus infections, 68-69
 in HIV infection, 70
 in parvovirus infections, 69
 in red blood cell isoimmunization, 61-65
 in small for gestational age fetus, 70-71
 in syphilis, 70
 in tachyarrhythmias, 72-73
 in thrombocytopenic disorders, 65-66
 in thyroid disease, 71-72
 in toxoplasmosis, 67-68
 in varicella infection, 70
 Umbilical cord occlusion, asphyxia in, 310
 Urologic system, congenital anomalies of, in diabetic pregnancies, 519
- Vagotomy model, of ARDS, 772
- Varicella, umbilical blood sampling in, 70
 Vasculopathy, in diabetic pregnancies, congenital anomalies and, 519-520
 intrauterine death and, 550
 Vasodilators, in pulmonary hypertension, 137
 Vasopressin, in labor initiation, 12
 Vasopressors, in pulmonary hypertension, 136
 Ventilation, mechanical, in pulmonary hypertension, 134-135
 surfactant therapy with, 750-752
 Ventral wall defects, delivery route for, 94-97
 Ventricular hypoplasia, in hypoplastic left-heart syndrome, 145
 Very low birth weight infants, handicapped, prevalence of, 263-277
 Viral pneumonia, surfactants in, 775
 Visual evoked potentials, in perinatal asphyxia, 451-461
 animal studies of, 454
 in full term infants, 456-458
 in preterm infants, 456
 vs. somatosensory evoked potentials, 458-459, 470-472
 in respiratory distress syndrome (neonatal), 454-455
 Vitamin A, as teratogen, 527
 Vitamin E, in cerebral hypoxia-ischemia, 418
- White classification, of diabetes mellitus, 514
 Wilhelmy-Langmuir balance, in surfactant surface tension measurement, 669-671
- Xanthine oxidase, in cerebral hypoxia-ischemia, 413-414
- Yolk sac, hyperglycemia effects on, 521-522
- Zidovudine (azidothymidine), in HIV infection, in pregnancy, 48-53
 Zinc deficiency, congenital anomalies in, 527

